Repurposing Clinical Agents for Chemical Exchange Saturation Transfer Magnetic Resonance Imaging: Current Status and Future Perspectives
Overview
Authors
Affiliations
Molecular imaging is becoming an indispensable tool to pursue precision medicine. However, quickly translating newly developed magnetic resonance imaging (MRI) agents into clinical use remains a formidable challenge. Recently, Chemical Exchange Saturation Transfer (CEST) MRI is emerging as an attractive approach with the capability of directly using low concentration, exchangeable protons-containing agents for generating quantitative MRI contrast. The ability to utilize diamagnetic compounds has been extensively exploited to detect many clinical compounds, such as FDA approved drugs, X-ray/CT contrast agents, nutrients, supplements, and biopolymers. The ability to directly off-label use clinical compounds permits CEST MRI to be rapidly translated to clinical settings. In this review, the current status of CEST MRI based on clinically available compounds will be briefly introduced. The advancements and limitations of these studies are reviewed in the context of their pre-clinical or clinical applications. Finally, future directions will be briefly discussed.
Su H, Chan K ACS Nano. 2024; 18(50):33775-33791.
PMID: 39642940 PMC: 11656841. DOI: 10.1021/acsnano.4c05923.
Mohanta Z, Gori S, McMahon M ACS Omega. 2024; 9(26):27755-27765.
PMID: 38973929 PMC: 11223143. DOI: 10.1021/acsomega.4c02296.
Metabolic brain imaging with glucosamine CEST MRI: in vivo characterization and first insights.
Rivlin M, Perlman O, Navon G Sci Rep. 2023; 13(1):22030.
PMID: 38086821 PMC: 10716494. DOI: 10.1038/s41598-023-48515-5.
Contrasting Properties of Polymeric Nanocarriers for MRI-Guided Drug Delivery.
Lopuszynska N, Weglarz W Nanomaterials (Basel). 2023; 13(15).
PMID: 37570481 PMC: 10420849. DOI: 10.3390/nano13152163.
Bo S, Zhang D, Ma M, Mo X, Stabinska J, McMahon M Pharmaceuticals (Basel). 2023; 16(5).
PMID: 37242423 PMC: 10223748. DOI: 10.3390/ph16050639.